Teiji Kuzuya

Profile Information

Affiliation: Professor, Department of Gastroenterology and Hepatology, Fujita Health University School of Medicine

Degree: 博士（医学）(名古屋大学)

ORCID iD: https://orcid.org/0000-0002-2229-990X
J-GLOBAL ID: 201101073782477483
researchmap Member ID: 6000030051

Research Interests

Research Areas

Life sciences / Gastroenterology / 肝臓病学

Research History

Feb, 2023 - Present

Professor, Gastroenterology and Hepatology, Fujita Health University
Apr, 2022 - Jan, 2023

Fujita Health University
Apr, 2021 - Jan, 2023

Fujita Health University
Apr, 2020 - Mar, 2021

Fujita Health University
Jan, 2020 - Mar, 2020

講師, 消化器内科, 名古屋大学医学部附属病院
Feb, 2014 - Dec, 2019

Nagoya University
Jan, 2012 - Jan, 2014

Nagoya University
Apr, 2011 - Mar, 2012

Nagoya University
Apr, 2009 - Mar, 2011

消化器科, 武蔵野赤十字病院
Apr, 2008 - Mar, 2009

消化器内科, 名古屋共立病院
Jul, 2002 - Dec, 2004

消化器科, 大垣市民病院
Apr, 2000 - Jun, 2002

消化器科, 名古屋掖済会病院
Apr, 1998 - Mar, 2000

研修医, 名古屋掖済会病院

Education

Apr, 2004 - Mar, 2008

Department of Gastroenterology and Hepatology, Graduate School of Medicine, Nagoya University
Apr, 1992 - Mar, 1998

Faculty of Medicine, Mie University

Major Professional Memberships

Major Papers

201

Characteristics and Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Atezolizumab/Bevacizumab Combination Therapy Who Achieved Complete Response.

Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yoshihiko Tachi, Takeshi Ukai, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka …

Current oncology (Toronto, Ont.), 31(10) 6218-6231, Oct 16, 2024 Peer-reviewedLead authorCorresponding author
Altered intestinal Streptococcus anginosus and 5α-reductase gene levels in patients with hepatocellular carcinoma and elevated Bacteroides stercoris in atezolizumab/bevacizumab non-responders.

Tadashi Fujii, Teiji Kuzuya, Nobuhiro Kondo, Kohei Funasaka, Eizaburo Ohno, Yoshiki Hirooka, Takumi Tochio

Journal of medical microbiology, 73(9), Sep, 2024 Peer-reviewed
Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma

Teiji Kuzuya, Naoto Kawabe, Hisanori Muto, Yuryo Wada, Gakushi Komura, Takuji Nakano, Hiroyuki Tanaka, Kazunori Nakaoka, Eizaburo Ohno, Kohei Funasaka …

Current Oncology, 31(8) 4225-4240, Jul 26, 2024 Peer-reviewedLead authorCorresponding author
Clinical Outcomes With Lenvatinib in Patients Previously Treated With Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma.

Hisanori Muto, Teiji Kuzuya, Naoto Kawabe, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Senju Hashimoto …

Anticancer research, 43(10) 4673-4682, Oct, 2023 Peer-reviewedLead authorCorresponding author
Clinical Outcomes of Cabozantinib in Patients Previously Treated with Atezolizumab/Bevacizumab for Advanced Hepatocellular Carcinoma—Importance of Good Liver Function and Good Performance Status

Teiji Kuzuya, Naoto Kawabe, Mizuki Ariga, Eizaburo Ohno, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Takeshi Takahara …

Cancers, 15(11), May, 2023 Peer-reviewedLead authorCorresponding author
Polymyalgia rheumatica during combination therapy with atezolizumab plus bevacizumab for advanced hepatocellular carcinoma.

Naoki Dosoden, Teiji Kuzuya, Yumi Ito, Jo Nishino, Eizaburo Ohno, Naoto Kawabe, Senju Hashimoto, Yoshiki Hirooka, Hidekata Yasuoka

Clinical journal of gastroenterology, 16(4) 567-571, Apr 18, 2023 Peer-reviewedCorresponding author
Clinical Outcomes of Ramucirumab as Post-treatment Following Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular Carcinoma.

Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, Kohei Funasaka, Mitsuo Nagasaka, Yoshihito Nakagawa, Ryoji Miyahara, Tomoyuki Shibata, Takeshi Takahara, Yutaro Kato …

Anticancer research, 42(4) 1905-1910, Apr, 2022 Peer-reviewedLead authorCorresponding author
Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.

Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, Ryoji Miyahara, Akira Sawaki, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yohei Miyachi, Arisa Mii …

Oncology, 100(1) 1-10, Nov 3, 2021 Peer-reviewedLead authorCorresponding author
Transient deterioration of albumin-bilirubin scores in early post-dose period of molecular targeted therapies in advanced hepatocellular carcinoma with 50% or higher liver occupation: A STROBE-compliant retrospective observational study.

Hisanori Muto, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

Medicine, 100(31) e26820, Aug 6, 2021 Peer-reviewedCorresponding author
Initial Experience of Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma in Clinical Practice

Teiji Kuzuya, Naoto Kawabe, Senju Hashimoto, Ryoji Miyahara, Takuji Nakano, Kazunori Nakaoka, Hiroyuki Tanaka, Yohei Miyachi, Arisa Mii, Yoshinao TanahashiI …

CANCER DIAGNOSIS & PROGNOSIS, 1(1) 19-22, Apr, 2021 Peer-reviewedLead authorCorresponding author
Complete response of advanced hepatocellular carcinoma achieved by sorafenib dose re-escalation after failure of long-term low-dose-sorafenib treatment combined with transcatheter arterial chemoembolization: a case report.

Hisanori Muto, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

Clinical journal of gastroenterology, 13(3) 397-402, Jun, 2020 Peer-reviewedCorresponding author
Initial Experience of Ramucirumab Treatment After Lenvatinib Failure for Patients With Advanced Hepatocellular Carcinoma.

Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

Anticancer research, 40(4) 2089-2093, Apr, 2020 Peer-reviewedLead authorCorresponding author
Sorafenib vs. Lenvatinib as First-line Therapy for Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis.

Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

Anticancer research, 40(4) 2283-2290, Apr, 2020 Peer-reviewedLead authorCorresponding author
Favorable radiological antitumor response at 2 weeks after starting lenvatinib for patients with advanced hepatocellular carcinoma.

Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

Hepatology research : the official journal of the Japan Society of Hepatology, 50(3) 374-381, Mar, 2020 Peer-reviewedLead author
Relationship Between Adverse Events and Microbiomes in Advanced Hepatocellular Carcinoma Patients Treated With Sorafenib.

Kenta Yamamoto, Teiji Kuzuya, Takashi Honda, Takanori Ito, Yoji Ishizu, Masanao Nakamura, Ryoji Miyahara, Hiroki Kawashima, Masatoshi Ishigami, Mitsuhiro Fujishiro

Anticancer research, 40(2) 665-676, Feb, 2020 Peer-reviewed
Efficacy and Safety of Sorafenib in Unresectable Hepatocellular Carcinoma with Bile Duct Invasion.

Taku Tanaka, Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Mitsuhiro Fujishiro

Oncology, 98(9) 621-629, 2020 Peer-reviewedCorresponding author
Successful Treatment of Hepatocellular Carcinoma with Regorafenib after Sorafenib-induced Hypersensitivity.

Naoki Yoshioka, Teiji Kuzuya, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Masatoshi Ishigami, Mitsuhiro Fujishiro

Internal medicine (Tokyo, Japan), 58(19) 2803-2808, Oct 1, 2019 Peer-reviewedCorresponding author
Clinical characteristics and outcomes of candidates for second-line therapy, including regorafenib and ramucirumab, for advanced hepatocellular carcinoma after sorafenib treatment.

Teiji Kuzuya, Masatoshi Ishigami, Takanori Ito, Yoji Ishizu, Takashi Honda, Tetsuya Ishikawa, Yoshiki Hirooka, Mitsuhiro Fujishiro

Hepatology research : the official journal of the Japan Society of Hepatology, 49(9) 1054-1065, Sep, 2019 Peer-reviewedLead authorCorresponding author
Complete response by vitamin K2 analog monotherapy in sorafenib-failure advanced hepatocellular carcinoma: A case report.

Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Yoshiki Hirooka, Hidemi Goto

Hepatology research : the official journal of the Japan Society of Hepatology, 49(3) 360-364, Mar, 2019 Peer-reviewedLead author
Prognostic Factors Associated with Postprogression Survival in Advanced Hepatocellular Carcinoma Patients Treated with Sorafenib Not Eligible for Second-Line Regorafenib Treatment.

Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Isao Nakano, Yoshiki Hirooka, Hidemi Goto

Oncology, 95(2) 91-99, 2018 Peer-reviewedLead author
Fever within 2 Weeks of Sorafenib Therapy Predicts Favorable Treatment Efficacy in Patients with Advanced Hepatocellular Carcinoma.

Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Tetsuya Ishikawa, Isao Nakano, Hidemi Goto, Yoshiki Hirooka

Oncology, 91(5) 261-266, 2016 Peer-reviewedLead author
Early Clinical Response after 2 Weeks of Sorafenib Therapy Predicts Outcomes and Anti-Tumor Response in Patients with Advanced Hepatocellular Carcinoma.

Teiji Kuzuya, Masatoshi Ishigami, Yoji Ishizu, Takashi Honda, Kazuhiko Hayashi, Yoshiaki Katano, Yoshiki Hirooka, Tetsuya Ishikawa, Isao Nakano, Hidemi Goto

PloS one, 10(9) e0138776, 2015 Peer-reviewedLead author
Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.

Teiji Kuzuya, Yasuhiro Asahina, Kaoru Tsuchiya, Keisuke Tanaka, Yuichiro Suzuki, Takahide Hoshioka, Shinji Tamaki, Tomoji Kato, Yutaka Yasui, Takahiro Hosokawa …

Oncology, 81(3-4) 251-8, 2011 Peer-reviewedLead author
Regulation of branched-chain amino acid catabolism in rat models for spontaneous type 2 diabetes mellitus.

Teiji Kuzuya, Yoshiaki Katano, Isao Nakano, Yoshiki Hirooka, Akihiro Itoh, Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda, Hidemi Goto, Yuko Fujita …

Biochemical and biophysical research communications, 373(1) 94-8, Aug 15, 2008 Peer-reviewedLead author
Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma.

Teiji Kuzuya, Yoshiaki Katano, Takashi Kumada, Hidenori Toyoda, Isao Nakano, Yoshiki Hirooka, Akihiro Itoh, Masatoshi Ishigami, Kazuhiko Hayashi, Takashi Honda …

Journal of gastroenterology and hepatology, 22(11) 1929-35, Nov, 2007 Peer-reviewedLead author
Contrast-enhanced ultrasonographic assessment of the response of Ménétrier disease to Helicobacter pylori eradication therapy.

Teiji Kuzuya, Takashi Kumada, Seiki Kiriyama, Yasuhiro Sone, Makoto Tanikawa, Yasuhiro Hisanaga, Hidenori Toyoda, Kazuhiko Hayashi, Koji Nonogaki, Junichi Shimizu …

Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 25(8) 1099-103, Aug, 2006 Peer-reviewedLead author

Major Misc.

709

【免疫チェックポイント阻害剤を巡る問題;適切なマネージメント】

中本安成, 山下竜也, 葛谷貞二, 平岡淳, 小笠原定久

肝臓, 64(5) 217-234, May, 2023
脂肪肝 NAFLD肝がんにおける肝癌薬物療法の注意点

葛谷貞二, 廣岡芳樹

Medical Practice, 40(9) 1405-1407, 2023 Lead author
How to use IO-IO and IO-anti-VEGF for HCC

葛谷貞二, 川部直人, 廣岡芳樹

肝胆膵, 85(3) 383-391, Sep, 2022 Lead author
Precautions in Systemic Therapy in Patients with NAFLD-HCC

葛谷貞二, 川部直人, 廣岡芳樹

臨床消化器内科, 37(8) 940-946, Jul, 2022 Lead author
Initial experience of ramucirumab therapy after atezolizumab+bevacizumab for patients with advanced hepatocellular carcinoma

葛谷貞二, 川部直人, 廣岡芳樹

肝胆膵, 84(5) 700-701, May, 2022 Lead author
Atezolizumab plus bevacizumab for advanced hepatocellular carcinoma in real-world practice

葛谷貞二, 川部直人, 廣岡芳樹

肝臓クリニカルアップデート, 7(1) 13-18, Oct, 2021 Lead author
検査値の読み方飢餓状態にみられた高度肝障害の1例

宮地洋平, 葛谷貞二, 廣岡芳樹

臨床消化器内科, 36(12) 1586-1591, Oct, 2021 Corresponding author
検査値の読み方アルコール性肝硬変に合併した膵性腹水の1例

三井有紗, 葛谷貞二, 廣岡芳樹

臨床消化器内科, 36(6) 686-691, May, 2021 Corresponding author
Molecular targeted therapy for advanced hepatocellular carcinoma

葛谷貞二, 川部直人, 廣岡芳樹

医学と薬学, 78(4) 371-376, Mar, 2021 Lead author
【肝癌の新たな流れと治療の進歩】進行肝癌に対する分子標的治療薬

葛谷貞二, 川部直人, 廣岡芳樹

医学と薬学, 78(4) 371-376, Mar, 2021 Lead author
進行肝細胞癌に対するレンバチニブPD後のラムシルマブ治療の初期経験

葛谷貞二, 石上雅敏, 杉山由晃, 吉岡直輝, 水野和幸, 武藤久哲, 横山晋也, 田中卓, 山本健太, 伊藤隆徳 …

Pharma Medica, 39(2) 72-73, Feb, 2021 Lead author
検査値の読み方薬剤起因性と考えられた胆管消失症候群の1例

宮地洋平, 葛谷貞二, 廣岡芳樹

臨床消化器内科, 36(2) 223-228, Jan, 2021 Corresponding author
Regorafenib for advanced HCC patients in the RESORCE-out group

葛谷貞二, 川部直人, 廣岡芳樹

肝胆膵, 81(5) 925-930, Nov, 2020 Lead author
Ramucirumab therapy for lenvatinib-failed HCC patients

葛谷貞二, 川部直人, 廣岡芳樹

肝胆膵, 81(5) 979-985, Nov, 2020 Lead author
Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma.

葛谷貞二, 川部直人, 廣岡芳樹

月刊消化器・肝臓内科, 8(5) 494-501, Nov, 2020 Lead author
新しい診断・薬の情報アテゾリズマブ(テセントリク)+ベバシズマブ(アバスチン)の併用療法一次治療としてソラフェニブに優越性を示したはじめての薬物療法

葛谷貞二, 川部直人, 廣岡芳樹

肝臓クリニカルアップデート, 6(2) 265-270, Oct, 2020 Lead author
Initial experience of ramucirumab therapy for patients with advanced hepatocellular carcinoma in clinical practice

葛谷貞二, 石上雅敏, 藤城光弘

肝臓クリニカルアップデート, 6(1) 63-69, May, 2020 Lead author
【進化する肝細胞癌の薬物療法-2019 Update(Part 2)】免疫チェックポイント阻害剤による単剤治療一次治療としてのニボルマブによる第III相試験のデザイン(CheckMate 459試験)

葛谷貞二, 石上雅敏, 藤城光弘

肝胆膵, 79(3) 517-521, Sep, 2019 Lead author
【枠組みとケースから考える-消化器薬の選び方・使い方】消化器内科スペシャリストは何を考えて処方するか

野々垣浩二, 竹田欽一, 葛谷貞二

Medicina, 56(1) 8-16, Jan, 2019
【枠組みとケースから考える-消化器薬の選び方・使い方】悪性腫瘍の化学療法肝細胞がん

葛谷貞二, 石上雅敏

Medicina, 56(1) 144-147, Jan, 2019 Lead author
【急速に変貌する肝細胞癌の薬物療法2018 Update】レゴラフェニブレゴラフェニブの1年間の使用経験から学んだこと

葛谷貞二, 石上雅敏, 廣岡芳樹

肝胆膵, 77(2) 339-346, Aug, 2018 Lead author
【肝癌分子標的治療と今後の展望】TACEなど既存治療のポジショニング新薬の登場でいかに変わるか

伊藤隆徳, 葛谷貞二, 石上雅敏, 廣岡芳樹

消化器・肝臓内科, 4(1) 86-92, Jul, 2018 Corresponding author
3年半ぶりのソラフェニブ増量にて完全奏功が得られた進行肝細胞癌の1例

武藤久哲, 葛谷貞二, 横山晋也, 田中卓, 山本健太, 安藤祐資, 伊藤隆徳, 安田諭, 石津洋二, 本多隆 …

The Liver Cancer Journal, (Suppl.1) 52-53, Jun, 2018
【肝細胞癌の化学療法が変わる】ソラフェニブ治療の有効性どの時点で次治療に移行するか画像的PDに着目して

葛谷貞二, 石上雅敏, 後藤秀実

肝胆膵, 75(2) 287-294, Aug, 2017 Lead author
【内科医が知っておくべき肝癌治療最前線】ソラフェニブ治療導入時期とセカンドラインを考慮すべきタイミング

葛谷貞二, 石上雅敏, 後藤秀実

消化器・肝臓内科, 2(1) 76-82, Jul, 2017 Lead author
ソラフェニブ単独治療にてCRが得られた進行肝細胞癌2例

安田諭, 葛谷貞二, 田中卓, 山本健太, 安藤祐資, 伊藤隆徳, 野村彩, 加藤幸一郎, 石津洋二, 本多隆 …

The Liver Cancer Journal, 9(1) 80-81, Jun, 2017 Corresponding author
【治療前・中・後のやること&患者説明にもっと自信をつけよう肝胆膵の治療と看護を学びなおし!】PEIT(経皮的エタノール注入療法)

葛谷貞二, 石上雅敏, 後藤秀実

消化器外科Nursing, 20(3) 202-205, Mar, 2015 Lead author
【治療前・中・後のやること&患者説明にもっと自信をつけよう肝胆膵の治療と看護を学びなおし!】RFA(経皮的ラジオ波焼灼療法)

葛谷貞二, 石上雅敏, 後藤秀実

消化器外科Nursing, 20(3) 206-210, Mar, 2015 Lead author
Clinical trial of percutaneous radio frequency ablation therapy by two-step insertion method using VirtuTRAX^TM instrument navigator

葛谷貞二, 石津洋二, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 本多隆, 林和彦 …

肝臓, 54(12) 850-853, Dec, 2013 Lead author
放射線治療およびソラフェニブが奏効した巨大骨盤骨転移を伴うCK19陽性肝細胞癌の1症例

葛谷貞二, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 本多隆 …

Liver Cancer, 19 71-75, Nov, 2013 Lead author
The relationship between the fever and the disappearance or decrease of lesion contrast on contrast enhanced CT images after 2 weeks of sorafenib treatment for patients with advanced hepatocellular carcinoma

葛谷貞二, 石上雅敏, 新家卓郎, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 石津洋二, 本多隆 …

肝臓, 54(7) 505-506, Jul, 2013 Lead author
ソラフェニブ投与後、腫瘍濃染の消失・減弱(阻血性変化)が一旦認められたものの、その後の経過で腫瘍内血流が再燃した進行肝細胞癌の3例

葛谷貞二, 片野義明, 今井則博, 阿知波宏一, 荒川恭宏, 山田恵一, 中野聡, 増田寛子, 石津洋二, 本多隆 …

The Liver Cancer Journal, 4(2) 140-141, Jun, 2012 Lead author
バンコマイシン投与によって難治性肝性脳症が改善し肝細胞癌に対する肝動脈化学塞栓療法が可能となった1例

葛谷貞二, 竹田欽一, 宇都宮節夫, 多賀雅浩, 川田登, 池田誉, 今井則博, 水谷佳貴, 広瀬健, 石川哲也

癌と化学療法, 38(6) 995-1001, Jun, 2011 Lead author
Sorafenib therapy for advanced hepatocellular carcinoma with Vp3 or 4 portal vein tumor thrombosis

葛谷貞二, 土谷薫, 田中佳祐, 鈴木雄一朗, 星岡賢英, 玉城信治, 加藤知爾, 安井豊, 細川貴範, 上田研 …

肝臓, 52(5) 325-326, May, 2011 Lead author
【透析診療における分子バイオマーカーの新たな展開】各論-日常透析診療に役立つ分子バイオマーカー肝臓病

葛谷貞二, 泉並木

臨床透析, 27(4) 405-411, Apr, 2011 Lead author
【B型肝炎治療の最新戦略】核酸アナログに対する治療反応性に基づくB型慢性肝炎の治療戦略

黒崎雅之, 葛谷貞二, 泉並木

消化器内科, 52(1) 99-102, Jan, 2011
Liver、Pancreas、Biliary Tract Cancer肝・胆・膵癌肝癌分子標的治療の基礎と臨床進行肝細胞癌に対する分子標的薬ソラフェニブの治療成績

葛谷貞二, 土谷薫, 泉並木

癌と化学療法, 37(10) 1883-1886, Oct, 2010 Lead author
Significance of PIVKA-II in sorafenib therapy for advanced hepatocellular carcinoma

葛谷貞二, 土谷薫, 田中佳祐, 鈴木雄一朗, 星岡賢英, 玉城信治, 加藤知爾, 安井豊, 田中智大, 細川貴範 …

肝臓, 51(7) 403-404, Jul, 2010 Lead author
[A case of hepatitis B-related multiple hepatocellular carcinomas, most of which lead to necrosis possibly due to the implantation of an arterial infusion catheter].

Teiji Kuzuya, Kinichi Takeda, Setsuo Utsunomiya, Masahiro Taga, Noboru Kawata, Takashi Ikeda, Norihiro Imai, Yoshitaka Mizutani, Ken Hirose, Tetsuya Ishikawa …

Gan to kagaku ryoho. Cancer & chemotherapy, 36(12) 2377-2379, Nov, 2009 Peer-reviewedLead author
大腸癌術前に各種画像検査によって多発肝類上皮性血管内皮腫と診断できた1例

葛谷貞二, 竹田欽一, 宇都宮節夫, 川田登, 池田誉, 今井則博, 水谷佳貴, 広瀬健, 石川哲也, 伊藤将倫 …

肝胆膵治療研究会誌, 7(1) 112-112, Aug, 2009 Lead author
2型糖尿病モデルラットにおける分岐鎖アミノ酸(BCAA)代謝とそれに対するBCAA代謝食摂取の影響

藤田裕子, 葛谷貞二, 村松雄治, Bajotto Gustavo, 下村吉治

アミノ酸研究, 1(1) 71-72, Mar, 2008
【肝細胞癌根治後の再発予防】初発B型肝細胞癌治療後のラミブジン投与の有用性

葛谷貞二, 片野義明, 熊田卓, 豊田秀徳, 土居崎正雄, 岩田浩史, 後藤新太郎, 舘佳彦, 竹田泰史, 西野正路 …

消化器科, 44(5) 500-505, May, 2007 Lead author
【肝癌治療前後の画像】ラジオ波焼灼療法-造影エコーとダイナミックMRIの比較

葛谷貞二, 熊田卓, 豊田秀徳, 桐山勢生, 曽根康博, 谷川誠, 久永康宏, 野々垣浩二, 清水潤一, 山内貴裕 …

消化器画像, 6(4) 490-497, Jul, 2004 Lead author
【肝癌局所療法の長期予後】肝細胞癌初回治療における肝切除と局所療法の長期予後の比較とその治療選択 JIS score,CLIP score,AFP-L3分画別に検討

葛谷貞二, 熊田卓, 豊田秀徳, 桐山勢生, 曽根康博, 谷川誠, 久永康宏, 野々垣浩二, 清水潤一, 川瀬直登 …

消化器科, 38(5) 504-512, May, 2004 Lead author
実例から学ぶ腸感染症(感染性腸炎)の診断とその問題点病原性大腸菌腸炎の内視鏡的検討

葛谷貞二, 林繁和, 小池光正

日本大腸検査学会雑誌, 18(1) 124-127, Sep, 2001 Lead author

Books and Other Publications

Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma

葛谷, 貞二

[s.n.], 2008

Research Projects

発癌機能因子に着目したテーラーメイド消化器癌早期診断の可能性

科学研究費助成事業, 基盤研究(C), 日本学術振興会, Apr, 2023 - Mar, 2026

藤井匡, 栃尾巧, 廣岡芳樹, 中川義仁, 長坂光夫, 舩坂好平, 渡辺彩子, 中岡和徳, 葛谷貞二

Profile Information

Research Interests

Research Areas

Research History

Education

Major Professional Memberships

Major Papers

Major Misc.

Books and Other Publications

Research Projects

Committee Memberships

Menu

Coauthors